Is the LHRH Agonist Recommended for Fertility Preservation ?
Kimura, K.; Iwamoto, M.; Tanaka, S.; Watanabe, T.; Aihara, T.; Sugimoto, T.; Miyara, K.; Hayashi, M.; Kouno, T.; Baba, S.; Kawashima, H.; Hashimoto, N.; Uchiyama, K.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(8): 1019-1021
2015
ISSN/ISBN: 0385-0684 PMID: 26321722 Document Number: 682722
The POEMS reportedan effect of goserelin for fertility preservation. The Clinical Practice Guideline for Breast Cancer by The Japanese Breast Cancer Society indicates that the use of the LHRH agonist (LHRHa) for preventing chemotherapy-induced early menopause is a grade C-1 recommendation, and its use for fertility preservation is a grade C-2 recommendation. Results from previous studies on the effects of LHRHa for fertility preservation have varied owing to differences in chemotherapy regimens, definitions of ovarian failure, and dosages of tamoxifen. In the POEMS, the primary endpoint of ovarian failure at 2 years was significantly lower, and the secondary endpoint of pregnancy outcomes was better in the combination group; however, precise interpretation is difficult because many cases were excluded. Currently, it is not necessary to revise The Clinical Practice Guideline; however, desirable results from future studies may allow the recommendation of a specific dosage of LHRHa for fertility preservation.